

RECORDATI: 2023 CORPORATE EVENTS' CALENDAR

Milan, 16th January 2023 – Recordati S.p.A. hereby communicates the calendar of corporate events for 2023:

21st February	Board of Directors' meeting to approve the 2022 preliminary consolidated results and the update of the Three-year Plan for 2023-2025. <i>At 4.00 pm (CET): presentation to the financial community at Borsa Italiana (Milan), with possibility to connect remotely</i>
16th March	Board of Directors' meeting to approve the 2022 consolidated financial statements and the draft of Recordati S.p.A.'s 2022 financial statements as well as the 2022 consolidated non-financial statement.
21st April	Annual Shareholders' Meeting to approve Recordati S.p.A.'s 2022 financial statements.
11th May	Board of Directors' meeting to approve the 2023 first quarter results, as additional voluntary financial reporting.
28th July	Board of Directors' meeting to approve the 2023 half-yearly report.
7th November	Board of Directors' meeting to approve the 2023 first nine months' results, as additional voluntary financial reporting.

Recordati S.p.A. announces that the payment of the balance of the 2022 financial year dividend is planned for 24th May 2023, on each outstanding share at 22nd May 2023 (ex-dividend rate) and record date 23rd May 2023, while the payment of the interim dividend for the 2023 financial year is planned for 22nd November 2023, on each outstanding share at 20th November 2023 (ex-dividend rate) and record date at 21st November 2023.

Recordati S.p.A. specifies that this press release is not a prevision of the existence of the conditions for the dividend distribution as per the above.

Any amendments to the above calendar as well as any further dedicated meetings/conference calls with the financial community will be promptly notified to the market and will be made available in the investor relations section of the company website.

Recordati (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan and Australia.

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered office
 VIA M. CIVITALI, 1
 20148 MILAN, ITALY
 TEL. +39 0248787.1
 FAX +39 0240073747

SHARE CAPITAL € 26,140,644.50 fully paid up
 BUS. REG. OF MILAN, MONZA, BRIANZA and LODI 00748210150
 TAX CODE/VAT NO. 00748210150
 MILAN ECONOMIC AND ADMINISTRATIVE INDEX (REA) 401832

Company subject to management and coordination by Rossini Luxembourg S.à.r.l



An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a specialised business dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was €1,580.1 million, operating income was €490.2 million and net income was €386.0 million.

Further information:

Recordati website: www.recordati.it

Investor Relations

Federica De Medici

(39) 02 48787146

email: investorelations@recordati.it

Investor Relations

Lucia Abbatantuoni

(39) 02 48787213

e-mail: investorelations@recordati.it

Press Office

Brunswick: Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: recordati@brunswickgroup.com

This document contains forward-looking statements relating to future events and future operating, economic and financial results of the Recordati group. By their nature, forward-looking statements involve risk and uncertainty because they depend on the occurrence of future events and circumstances. Actual results may therefore differ materially from those forecast as a result of a variety of reasons, most of which are beyond the Recordati group's control. The information on the pharmaceutical specialties and other products of the Recordati group contained in this document is intended solely as information on the activities of the Recordati Group, and, as such, it is not intended as a medical scientific indication or recommendation, or as advertising.